Methodology of clinical trials in dementia. Part II: Future trials— Recommendations
Because of the small magnitude of the improvement to be expected and the absence of indications of long-term benefits, it would seem that at present vasodilators are of minor clinical value in the treatment of dementia. Further studies with better methodologies and longer follow-up periods … may lead to more favourable conclusions.
KeywordsFuture Trial Ergot Alkaloid Senile Dementia Demented Patient Geriatric Ward
Unable to display preview. Download preview PDF.
- Cox, D. R. (1972). Regression model and life-tables. J. Roy. Stat. Soc. (B), 134, 187–220.Google Scholar
- Elandt-Johnson, R. C. and Johnson, N. L. (1979). Survival models and data analysis. In Bradley, R. A., Hunter, J. S., Kendall, D. G. and Watson, G. S. (eds), Wiley Series in Probability and Mathematical Statistics, Wiley Interscience, New York.Google Scholar
- Mortimer, J. A. and Schuman, L. M. (1981). Epidemiology of Dementia, Oxford University Press, Oxford.Google Scholar
- Roth, M. (1955). The natural history of mental disorder in old age. J. Ment. Sci., 102, 281–301.Google Scholar
- Small, G. W. and Jarvik, L. F. (1983). The dementia syndrome. Lancet, 2, 1443–5.Google Scholar